Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 56ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × romiplostim × Lymphoid × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡